MXCT
MAXCYTE, INC.
NASDAQ · Healthcare · Medical - Devices · US
$1.39
−4.79%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.47
From 52W high−21.02%
Volume855822.00
Market cap$143.46M
P/E (TTM)—
P/S (TTM)4.6x
Div yield—
Key dataNov 4, 2026
Open
$1.47
From 52W high
−21.02%
Volume
855822.00
Market cap
$143.46M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
49.9
MomentumView details →
1D Return
−4.79%
YTD Return
−11.95%
SummaryUpdated Jun 1, 2026
MaxCyte, Inc. (NASDAQ:MXCT) is a global life sciences company founded in 1998 and headquartered in Rockville, Maryland. The company specializes in cell engineering technology that enables the development of next-generation cell therapies. MaxCyte went public in July 2021 and has established itself as a key enabler in the emerging cell and gene therapy industry. The company's electroporation technology platform has supported the development of CASGEVY, the first FDA-approved non-viral cell therapy, and maintains partnerships with numerous biotechnology and pharmaceutical companies developing cell-based treatments.
Similar companies
Latest newsMore news →
MaxCyte raised its 2026 revenue guidance to approximately $34 million, including approximately $28 million from its core business and $6 million in SPL program-related revenue.21d agoMaxCyte reported preliminary third-quarter 2026 revenue of $9.1 million, including $8.1 million from its core business, up 26% year over year, and $1.0 million in SPL program-related revenue.21d agoMaxCyte granted inducement stock options for 220,000 shares and a restricted stock unit award for 110,000 shares to Sidharth Kapileshwar in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development Officer.54d ago